Lipid interactions with human antiphospholipid antibody, β2-glycoprotein 1, and normal human IgG using the fluorescent probes NBD-PE and DPH

Biochimica et Biophysica Acta - Biomembranes

Volumn 1372, Issue 1, 1998, Pages 45-54

  Tang, Daxin ^a   Borchman, Douglas ^a   Harris, Nigel ^b   Pierangeli, Silvia ^b  

^a University of Louisville School of Medicine   (United States)

^b MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

2 GP1; Antiphospholipid antibody; Cardiolipin; DPH; Fluorescence; NBD PE; Protein binding

Indexed keywords

1,6 DIPHENYL 1,3,5 HEXATRIENE; BETA2 GLYCOPROTEIN 1; CARDIOLIPIN; FLUORESCENT DYE; IMMUNOGLOBULIN; PHOSPHOLIPID ANTIBODY;

ANTIBODY DETECTION; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE SPECTROSCOPY; HUMAN; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; THROMBOSIS;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; BETA 2-GLYCOPROTEIN I; CATTLE; DIPHENYLHEXATRIENE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE POLARIZATION; FLUORESCENT DYES; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULIN G; LIPID METABOLISM; LIPIDS; LIPOSOMES; PHOSPHATIDYLETHANOLAMINES;

EID: 0032562958     PISSN: 00052736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0005-2736(98)00028-5     Document Type: Article

References (49)

1. E.N. Harris, Antiphospholipid antibodies and cardiovascular disease, in: R.B. Francis (Ed.), Atherosclerotic Cardiovascular Disease, Hemostasis, and Endothelial Function, Marcel Dekker, New York, 1992, pp. 237-276.
2. Triplett D.A., Brandt J.T. Lupus anticoagulants: misnomer, paradox, riddle, epiphenomena. Hematol. Pathol. 2:1988;121-143.
3. Love P.E., Santoro S.A. Antiphospholipid antibodies: anticardiolipin and lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders: prevalence and clinical significance. Ann. Intern. Med. 12:1990;682-698.
4. Harris E.N. Syndrome of the Black Swan. Br. J. Rheumatol. 26:1987;324-326.
5. Asherson R.A. A 'primary' antiphospholipid syndrome? J. Rheumatol. 15:1988;1742-1746.
6. Alarcon-Segovia D., Sanchez-Guerrero J. J. Rheumatol. 16:1989;482-488.
7. Harris E.N., Chan J.K.H., Asherson R.A., Aber V.R., Ghavari A.E., Hughes G.R.V. Thrombosis, recurrent fetal loss, thrombocytopenia; predictive value of IgG anticardiolipin antibodies. Arch. Intern. Med. 88:1990;112-116.
8. Lockshin M.D., Druzin M.L., Qatar T. Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibodies. Am. J. Obstet. Gynecol. 160:1989;439-443.
9. Alving B.M., Barr C.F., Tang D.D. Correlation between lupus anticoagulants and anti cardiolipin antibodies in patients with prolonged activated partial thromboplastin times. Am. J. Med. 88:1990;112-116.
10. Loizou S., Byron M.A., Englert H.R., Walport M.J., Hughes G.R.V. Association of quantitative anti-cardiolipin antibody levels with fetal loss. Q. J. Med. 68:1998;525-531.
11. Branch D.W., Dudley D.J., Mitchell M.D., Creightari K.A., Abbott J.M., Hammond E.H., Daynes R.A. Immunoglobulins G fractions from patients with antiphospholipid antibodies causes fetal death in Balb/c mice: a model for autoimmune fetal loss. Am. J. Obstet. Gynecol. 163:1990;210-216.
12. Blank M., Cohen J., Toder V., Shoenfeld Y. Proc. Natl. Acad. Sci. U.S.A. 88:1993;3069-3073.
13. Bakimer R., Fishman P., Blank M., Srednc B., Djaidetti M., Shoenfeld Y. Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3). J. Clin. Invest. 89:1992;1558-1563.
14. Smith H.R., Hansen C.L., Rose R., Canoso R.T. Autoimmune MRl-lpr/lpr mice are an animal model for the secondary antiphospholipid syndrome. J. Rheumatol. 17:1990;911-915.
15. A.E. Gharavi, Anti-phospholipid syndrome in mice, in: E.N. Harris, T. Exner, G.V.R. Hughes, R.A. Asherson (Eds.), Phospholipid Binding Antibodies, CRC Press, Boca Raton, FL, 1991, pp. 403-416.
16. Galli M., Beguin S., Lindout T., Hemker C.H. Inhibition of phospholipid and platelet-dependent prothrombinase activity in the plasms of patients with lupus anticoagulants. Br. J. Haematol. 72:1989;549-555.
17. Brandt J.T. Assay for phospholipid-dependent formation of thrombin and factor Xa: a potential method for quantifying lupus anticoagulants. Thromb. Haemost. 66:1991;453-458.
18. Marcus A.J., Ullman H.L., Safier L.B. Lipid composition of subcellular particles of human blood platelets. J. Lipid Res. 10:1969;108-115.
19. Triplett D.A., Brandt J.T. Lupus anticoagulants: misnomer, paradox, riddle, epiphenomena. Hematol. Pathol. 2:1988;121-143.
20. Oosting J.D., Derksen R.H.W.M., Entjes T.I., Bouma B.N., de Groot P.G. Lupus anticoagulant activity is frequently dependent on the presence of β2 glycoprotein1. Thromb. Haemostasis. 67:1992;499-502.
21. Galli M., Comfurius P., Barbui T., Zwaal R.F.A., Bevers E.M. Anticoagulant activity of beta 2-glycoprotein 1 is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb. Haemostasis. 68:1992;297-300.
22. Fleck R.A., Rapaport S.E., Rao L.V.M. Anti-prothrombin antibodies and the lupus anticoagulant. Blood. 72:1989;512-519.
23. Bevers E.M., Galli M., Barbui T., Camfurius P., Zwaa R.F.A. Lupus anticoagulant IgG's prothrombin. Thromb. Haemostasis. 66:1991;629-632.
24. Harris E.N., Gharavi A.E., Tincani A., Chan J.K.H., Balestrieri G., Hughes G.R.V. Affinity-purified anti-cardiolipin antibodies and anti-DNA antibodies. J. Clin. Lab. Immunol. 17:1985;155-162.
25. Harris E.N., Gharavi A.E., Wasley G.D., Hughes G.R.V. Use of an enzyme-linked immunosorbent assay and of inhibition studies to distinguish between antibodies to cardiolipin from patients with syphilis of autoimmune disorders. J. Infect. Dis. 157:1988;23-31.
26. Rauch J., Tannenbaum M., Tannenbaum H., Ramelion H., Cullis P.R., Tilcock C.P.S., Hope M.J., Janoff A.S. Human hybridoma lupus anticoagulants distinguish between bilayer and non-bilayer phase lipid systems. J. Biol. Chem. 261:1986;9672-9677.
27. Borchamn D., Harris E.N., Pierangeli S.S., Lamba O.P. Interactions and molecular structure of cardiolipin and beta 2-glycoprotein 1 (β2-GP1). Clin. Exp. Immunol. 102:1995;373-378.
28. D. Borchamn, D. Tang, N. Harris, S. Pierangeli, The structure of cardiolipin-phosphatidylcholine membranes and the effect of calcium and beta2-GP1 binding as explored by the fluorescence probe NBD-PE, submitted.
29. Borchman D., Tang D. Binding capacity of α-crystalline to bovine lens lipids. Exp. Eye Res. 63:1996;407-410.
30. Pierangeli S.S., Harris E.N., Goldsmith G.H., Gharavi A.E., Branch D.W., Dean W.L. Are immunoglobulins with lupus anticoagulant activity specific for phospholipids? Br. J. Haematol. 85:1993;124-132.
31. Pierangeli S.S., Goldsmith G.H., Krnic S., Harris E.N. Difference in functional activity of anticardiolipin antibodies from patients with syphilis and the antiphospholipid syndrome. Infect. Immunol. 62:1994;4081-4084.
32. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
33. Bartlett G.R. Phosphorus assay in column chromatography. J. Biol. Chem. 234:1959;466-468.
34. Harris E.N. Annotation: antiphospholipid antibodies. Br. J. Haematol. 74:1990;1-9.
35. Harris E.N., Pierangeli S.S., Birch D. Anticardiolipin wet workshop report: Vth International Symposium on Antiphospholipid Antibodies. Am. J. Clin. Pathol. 101(5):1994;616-624.
36. Borchman D., Oriki Y., Lamba O.P., Byrdwell W.C., Yappert M.C. Age and regional structural characterization of lipid hydrocarbon chains from human lenses by infrared, and near-infrared Raman, spectroscopies. Biospectroscopy. 2:1996;113-123.
37. Lentz B.R., Barro D.A., Hoechli M. Cholesterol-phosphatidycholine interactions in multilamellar vesicles. Biochemistry. 19:1980;1943-1954.
38. Wylie J., Pagano R.E. Kinetics of soluble lipid monomer diffusion between vesicles. Biochemistry. 20:1981;2783-2789.
39. Hong K., Baldwin P.A., Allen T.M., Papahadjopoulos D. Fluorometric detection of the bilayer-to-hexagonal phase transition in liposomes. Biochemistry. 27:1988;3947-3955.
40. Chattopadhyay A., London E. Spectropic and ionization properties of N-(1-nitronenz-2-oxa-1,3-diazol-4-yl)-labeled lipids in model membranes. Biochim. Biophys. Acta. 938:1988;24-34.
41. Pierangeli S., Goldsmith G., Harris E.N., Gharavi A.E., Branch D.W., Dean W.I. Arthritics Rheum. 35:1992;S69. Abstract.
42. Galli M., Comfurius P., Maasen C., Hemker H.C., Debiets M.H., Van Bred-Vriesman P.J.C., Barbui T., Zwaal R.F.A., Bevers E.M. Anticardiolipin antibodies directed not to cardiolipin but to a plasma protein cofactor. Lancet. 335:1990;1544-1547.
43. McNeil H.P., Simpson R.J., Chesterman C.N., Krilis S. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2 glycoprotein 1. Proc. Natl. Acad. Sci. U.S.A. 87:1990;4120-4124.
44. Matsuura E., Igarashi Y., Fujimoto M., Ichikawa K., Koike T. Anticardiolipin cofactors and differential diagnosis of autoimmune disease. Lancet. 336:1990;177-178.
45. Sammaritano L.R., Lockshin M.D., Gharavi A.E. Antiphospholipid antibodies differ in aPL cofactor requirement. Lupus. 1:1992;83-90.
46. Lauer S.A., Hempel U., Gries A., Frank K.H. Amino acid sequence of the region of beta 2-glycoprotein 1 (gp1) which mediates binding of autoantibodies to the cardiolipin-gp1 complex in humans. Immunology. 80:1993;22-28.
47. Hunt J., Krilis S. The fifth domain of β2-glycoprotein 1 contains a phospholipid binding site (cys281-cys288) and a region recognized by anticardiolipin antibodies. J. Immunol. 152:1994;653-659.
48. Levy R.A., Gharavi A.E., Sammaritano L.R., Habina L.V., Lockshin M.D. Fatty acid chain is a critical epitope for antiphospholipid antibody. J. Clin. Immunol. 10:1990;141-145.
49. Qamar T., Gharavi A.E., Levy R.A., Lockshin M.D. Lysophosphatidylethanolamine is the antigen to which apparent antibody to phosphatidylethanolamine binds. J. Clin. Immunol. 10:1990;260-263.